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The National Institute for Clinical Excellence
(NICE) whose unofficial acronyms are much funnier
and one (the National Institute for the Control of
Expenditure) probably more accurate has just, at the
time of writing, produced its final appraisal determi-
nation on newer drugs for epilepsy in adults (we still
await—how typical—the one for children). This final
determination on newer drugs compares them against
the older standard drugs for epilepsy. This is obvious,
but raises several problems. Firstly, valproate and car-
bamazepine are chosen as the older comparators. One
can see why since all new drugs are compared against
them in double blind trials. But there is very little
mention of phenobarbitone (an effective third world
anticonvulsant) or of phenytoin (still widely used in
this country). Perhaps some comparison should have
been made.
Secondly, it is also important to remember that val-
proate and carbamazepine were introduced into the
epilepsy world at a time when double blind controlled
trials did not have the supremacy they have today and
when standards for measuring efficacy were different.
Thirdly it is also important to remember that in terms
just of efficacy the older and the newer drugs cannot
be separated, despite determined efforts to do so. The
newer drugs stand or fall by their other properties and
side effects, not by their efficacy.
The “newer” drugs for epilepsy are a strange mixture
of the new and what I would term the older; can drugs
like lamotrigine and gabapentin, approaching the end
of their patent protection life, really be though of as
new? It is an odd reflection of the status of epilepsy
in British medical thinking that such drugs could be
considered “new”—they would not be in the case of
hypertension, for instance. The mix of “new” drugs
includes those licensed for monotherapy (lamotrigine
and topiramate) with those not so licensed. Should
they be lumped with those other drugs which are not
licensed either because they tried and failed, never
bothered or are too new, or, perhaps more sensibly,
assessed separately?
The appraisal concludes under the title of “Guidance”
that the old drugs (valproate and carbamazepine)
should be tried first unless there are (1) contraindica-
tions to the drugs, (2) they could interact with other
drugs, notably oral contraceptives, (3) they are al-
ready known to be poorly tolerated by the individual,
(4) the person is a woman of child-bearing potential.
This rule applies also to the elderly (in whom new
onset seizures are common) and those with learning
difficulty, in whom epilepsy is even more common
and often difficult to treat.
It is also recommended that people should be
treated with monotherapy and that “combination ther-
apy (adjunctive or “add on” therapy) should only be
considered when sequential attempts at monotherapy
with antiepileptic drugs have not resulted in seizure
freedom”. Since the second or subsequent drug will
be added into the first failed drug (and there may be
an interaction between them) there will be a time
when the patient will be taking two drugs. The first
drug should then be withdrawn; but one does not
usually do this at once since time must elapse to en-
sure that the second drug really is effective. By this
time the patient may well be near seizure freedom
for a year and be eligible for a driving licence and
unwilling to risk losing it again by drug withdrawal,
particularly if side effect free. Untidy perhaps and
not scientific—but human nature tends to be. At one
time whole conferences were devoted to “rational
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polytherapy” but clearly not now! But, most of the
newest new drugs do not hold monotherapy licences
and therefore theoretically will have to be combined
with something. I wonder what?
Are the recommendations fair and just? Well, if
I were the manufacturer of lamotrigine or oxcarba-
mazepine I would not think so. There is good reported
evidence that lamotrigine is as safe in pregnancy as
carbamazepine (and both significantly safer than val-
proate). The evidence for carbamazepine is the report,
but not that for lamotrigine. Why not? Since it is not
enzyme inducing many women, given an informed
choice, would prefer lamotrigine to carbamazepine.
For that reason; they should be given the evidence.
Oxcarbamazepine may have come late to these shores,
but has been in use on the continent for a long time and
is not, in that sense, a new drug. It is far less enzyme
inducing than carbamazepine and therefore will be
useful where carbamazepine is not. We should be told.
So, will these recommendations change my prac-
tice? No not really. Fit young men with new onset
epilepsy will get carbamazepine or valproate as they
always did, but women, the elderly and the learning
impaired will get the drug that suits either their femi-
ninity or be compatible with the other drugs that they
may be taking, now or in the future. That has always
been the case. Was the report worth its undoubted cost?
I really do not think so. Far better to have spent that
not inconsiderable sum on improving woefully inade-
quate epilepsy services in this country and leaving the
report until some important trials in this country have
been completed; then we might have a better idea as
to which drugs should be used first for which people
with epilepsy. Why the rush?
